[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer]
- PMID: 16897989
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer]
Abstract
Various kinds of combination chemotherapies with 5-FU as a base agent have been performed for patients with advanced or recurrent colorectal cancer. S-1 was a newly developed 5-FU derivative and was orally administered. One of the combination therapies with S-1 plus irinotecan (CPT-11) has also been expected to have a better therapeutic value. Recently this combination therapy has been undertaken by our department, and its clinical use and toxicities are described in this article.
Similar articles
-
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:131-4. Gan To Kagaku Ryoho. 2006. PMID: 16897988 Clinical Trial. Japanese.
-
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.Oncology. 2015;88(6):353-9. doi: 10.1159/000369976. Epub 2015 Jan 9. Oncology. 2015. PMID: 25592116 Clinical Trial.
-
[S-1 as a single agent for colorectal cancer].Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:121-4. Gan To Kagaku Ryoho. 2006. PMID: 16897986 Review. Japanese.
-
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:125-30. doi: 10.2217/14750708.3.1.125. Gan To Kagaku Ryoho. 2006. PMID: 16897987 Review. Japanese.
-
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.Anticancer Res. 2014 Aug;34(8):4595-9. Anticancer Res. 2014. PMID: 25075105
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical